Walgreens, the second-largest pharmacy chain in America with over 8,500 locations, is carrying a debt load that has sent alarm bells ringing across the retail industry. Five months after private equity firm Sycamore Partners completed its $18.8 billion leveraged buyout, financial figures released on January 16, 2026, reveal the full extent of the burden: $13.33 billion in total debt.

A Buyout Built on Borrowed Money

According to Walgreens' proxy statement, Sycamore financed 70.9 percent of the acquisition with debt—a staggering ratio that far exceeds the average debt level of 41 percent used by private equity firms in leveraged buyouts last year. This aggressive financial structure has transformed Walgreens from a struggling but solvent retailer into a company whose future hinges entirely on its ability to service massive obligations.

The math is unforgiving. Interest payments alone on $13 billion in debt consume cash that could otherwise fund store improvements, technology investments, or competitive wages. In an industry already operating on razor-thin margins, this financial engineering leaves virtually no room for error.

The Sycamore Track Record

Private equity's track record in retail provides little comfort. In the first quarter of 2024 alone, 70 percent of large U.S. corporate bankruptcies involved private equity-owned companies—a statistic that reflects how debt-heavy ownership structures can amplify industry headwinds into existential crises.

Sycamore itself has faced criticism for its handling of retail investments. When Sycamore-owned Nine West filed for bankruptcy in 2018, creditors accused the firm of a scheme to strip the brand for parts while sinking it with $800 million in debt. The company denied wrongdoing, but the case illustrates the risks inherent in highly leveraged retail ownership.

Cost-Cutting in Overdrive

Walgreens' response to its debt burden has been aggressive cost reduction. The company plans to close approximately 1,200 stores through 2027, shrinking its footprint by about 14 percent. For communities that rely on these pharmacies—often in areas already classified as "pharmacy deserts"—the closures represent more than corporate restructuring; they're a healthcare access crisis in the making.

The cuts extend beyond stores. In October, Walgreens fired most of its communications team and announced plans to close its downtown Chicago offices in 2026. Just weeks before Thanksgiving, the company slashed holiday pay for retail employees—a move that signaled the depth of its cost pressures and drew criticism from labor advocates.

The Bankruptcy Probability

Financial modeling platforms now peg Walgreens' probability of bankruptcy at 22.2 percent over the next 24 months. While that means a nearly four-in-five chance of survival, those odds are far from reassuring for employees, suppliers, landlords, and customers who depend on the chain.

The pharmacy industry itself is in distress. Rite Aid has closed all its locations after bankruptcy, CVS continues to shutter underperforming stores, and even smaller pharmacy brands are navigating financial and operational challenges. Against this backdrop, Walgreens' debt load positions it as particularly vulnerable to any deterioration in industry conditions.

What Private Equity Gets Wrong About Retail

The Walgreens situation exemplifies a recurring pattern in private equity retail investments: the assumption that cost cuts can outpace debt service. But retail depends on customer experience, employee engagement, and community presence—exactly the assets that tend to erode under financial pressure.

When stores close, remaining locations lose the network effects that drive pharmacy benefits manager contracts and supplier negotiations. When workers see holiday pay cut, customer service suffers. When investment in technology lags, competitors gain ground. Each cost reduction solves a short-term problem while potentially creating larger long-term challenges.

The Stakes for American Healthcare

Walgreens isn't just a retailer—it's healthcare infrastructure. The company operates one of the nation's largest pharmacy networks, provides vaccinations to millions of Americans, and serves as the primary pharmacy for countless Medicare and Medicaid beneficiaries. A bankruptcy or significant further retrenchment would have implications far beyond Walgreens' shareholders.

State and federal regulators may find themselves forced to intervene if pharmacy access becomes critically impaired. The closure of 1,200 stores will already strain healthcare delivery in many communities; a broader collapse would create a public health emergency.

What Investors Should Watch

While Walgreens went private in August 2025, its bonds still trade in public markets, and the company's fortunes affect publicly traded competitors, suppliers, and real estate investment trusts that lease space to pharmacies.

Key metrics to monitor include:

  • Same-store sales trends: Any acceleration in customer defection would signal the cost cuts are backfiring.
  • Pharmacy reimbursement rates: Pressure from PBMs could squeeze margins further.
  • Debt covenants: Violations could trigger accelerated repayment requirements.
  • Competitor moves: CVS and Amazon Pharmacy are positioned to absorb Walgreens customers if service deteriorates.

The Bottom Line

Walgreens' transformation from a publicly traded healthcare company to a heavily indebted private equity portfolio company represents one of the highest-stakes experiments in modern retail. Sycamore is betting that aggressive cost management can service $13 billion in debt while preserving enough operational capability to compete.

History suggests the odds are against them. For the millions of Americans who fill prescriptions at Walgreens, the stakes couldn't be higher.